Placental expression of arylamine N-acetyltransferases: Evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2

Pharmacology and Toxicology

Volumn 83, Issue 4, 1998, Pages 149-157

  Smelt, Valerie A ^a   Mardon, Helen J ^b   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ENVIRONMENTAL CHEMICAL; ISOENZYME;

ARTICLE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FETOPLACENTAL UNIT; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MOTHER FETUS RELATIONSHIP; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOBIOTIC METABOLISM;

EID: 0031769199     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1998.tb01461.x     Document Type: Article

References (54)

1. Adams, D. J., S. Seilman, Z. Amelizad, F. Oesch & C. J. Wolf: Identification of human cytochromes P450 analogous to forms induced by phenobarbitol and 3 methylchotanthrene in the rat. Biochem. J 1985, 232, 869-876.
2. Ala-Kokko, T. I., P. Pienimaki, R. Herva, A. I. Hollmen, O. Pelkonen & K. Vahakangas: Transfer of lidocaine and bupivacaine across the isolated-perfused human placenta. Pharmacology & Toxicology 1995, 77, 142-148.
3. Badawi, A. E. A. Hirvonen, D. A. Bell, N. P. Lang & F. F. Kadlubar: Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995, 55, 5230-5237.
4. Bell, D. A. E. A. Stephens, T. Castranio, D. M. Umbach, M. Watson, M. Deakin, I. Elder, C. Hendrichse, H. Duncan & R. C. Strange: Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995a, 55, 3537-3542.
5. Bell, D. A., A. F. Badawi, N. P. Lang, K. F. Ilett, F. F. Kadlubar & A. Hirvonen: Polymorphism in the N-acetyltransferase-1 (NAT1) polyadenylation signal-association of NAT1*10 with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 1995b, 55, 5226-5229.
6. Blum, M., A. Derrierre, D. M. Grant, M. Heim & U. A. Meyer: Molecular mechanisms of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA, 1991, 88, 5237 5241.
7. Bourget, P., C. Roulot & F. Hervé: Models for placental transfer studies of drugs. Clin. Pharmacokinet. Concepts 1995, 28, 161 180.
8. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
9. Butler, W. J., C. E. Schwartz, S. M. Sauer, J. T. Wilson & P. G. McDonough: Discordance in deoxyribonucleic acid analysis of fetus and trophoblast. Amer. J. Obstet. Gynaecol. 1988, 158, 642 645.
10. Caton, D.: Obstetric anesthesia and concepts of placental transport. A historical review of the nineteenth century. Anesthesiology 1977, 46, 132-137.
11. Coroneos, E., J. W. Gordon, S. L. Kelly, P. D. Wang & E. Sim: Drug metabolising N-acetyltransferase activity in human cell lines. Biochem. Biophys. Acta. 1991, 1073, 593-599.
12. Cribb, A. E., D. M. Grant, M. A. Miller & S. P. Spielburg: Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J. Pharmacol. Exp. Therap. 1991, 259, 1241 1246.
13. Cribb, A. E., H. Nakamura, D. M. Grant, M. A. Miller & S. P. Spielburg: Role of polymorphic and monomorphic human arylamine N-acetyl-transferases in determining sulfamethoxazole metabolism. Biochem. Pharmacol. 1993, 45, 1277-1282.
14. Deguchi, T., M. Mashimo & T. Suzuki: Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 1990, 265, 12757-12760.
15. Deguchi, T.: Physiology and molecular biology of arylamine N-acetyltransferases. Biomed. Res. 1992, 13, 231-242.
16. Derewlany, L. O. & G. J. Koren: Biotransformation of carcinogenic arylamines and arylamides by human placenta. Lab. Clin. Med. 1994, 124, 134-141.
17. Derewlany, L. O., B. Knie & G. Koren: Arylamine N-acetyltransferase activity of the human placenta. J. Pharmacol. Exp. Therap. 1994a, 269, 756-760.
18. Derewlany, L. O., B. Knie & G. Koren: Human placental transfer and metabolism of p-aminobenzoic acid. J. Pharmacol. Exp. Therap. 1994b, 269, 761-765.
19. Dilella, A. G. & S. L. C. Woo: Cloning large segments of genomic DNA using cosmid vectors. Meth. Enzymol. 1987, 152, 199-212.
20. Doll, M. A., W. Jiang, A. C. Deitz, T. D. Rustan & D. W. Hein: Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem. Biophys. Res. Commun. 1997, 233, 584-591.
21. Grant, D. M., M. Blum, M. Beer & V. A. Meyer: Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 1991, 39, 184-191.
22. Grant, D. M., N. C. Hughes, S. A. Janezic, G. H. Goodfellow, H. J. Chen, A. Gaedigk, V. L. Yu & R. Grewal: Human acetyltransferase polymorphisms. Mutation Res. 1997, 376, 61-70.
23. Hakkola, J., M. Pasanen, J. Hukkanen, O. Pelkonen, J. Maenpaa, R. J. Edwards, A. R. Boobis & H. Raunio: Expression of xenobiotic metabolizing cytochrome P450 forms in human full term placenta. Biochem. Pharmacol. 1996, 51, 403-411.
24. Hein, D. W., M. A. Doll, T. D. Ruston, K. Gray, Y. Feng, R. J. Ferguson & D. M. Grant: Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993, 14, 1633-1638.
25. Hickman, D. & E. Sim: N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem. Pharmacol. 1991, 42, 1007-1014.
26. Hickman, D., A. Risch, J. P. Camilleri & E. Sim: Genotyping human polymorphic arylamine N-acetyltransferase. Identification of new slow allotypic variants. Pharmacogenetics 1992, 2, 217 2613.
27. Hickman, D., J. Pope, S. D. Patil, G. Fakis, V. Smelt, L. A. Stanley, M. Payton, J. D. Unadkat & E. Sun: Expression of arylamine N-acetyltransferase in human intestine. Gut 1998, 42, 402-409.
28. Hoffman, D. & S. S. Hecht: Advances in tobacco carcinogenesis. In: Chemical carcinogenesis and mutagenesis I. Ed.: C. S. Cooper & P. L. Grover. Springer-Verlag 1990, pp. 63-102.
29. Ilett, K. F., D. M. Ingram, D. S. Carpenter, C. H. Teitel, N. P. Lang, F. F. Kadlubar & R. F. Minchin: Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem. Pharmacol. 1994, 47, 914-917.
30. Jenne, J. W.: Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of para-aminosalicylic acid in man. J. Clin. Invest. 1965, 44, 1992-2002.
31. Johnson, A. & R. J. Wapner: Mosaicism: Implications for postnatal outcome. Curr. Op. Obstet. Gynaecol. 1997, 9, 126-135.
32. Juchau, M. R., M. J. Namkung, D. L. Berry & P. K. Zachariah: Oxidative biotransformation of 2-acetylaminofluorene in fetal and placental tissues of humans and monkeys: Correlations with aryl hydrocarbon hydroxylase activities. Drug Metab. Dispos. 1975, 3, 494-501.
33. Lin, H. J., C. Y. Han, B. K. Lin & S. Hardy: Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics and Whites: Application to metabolic epidemiology. Amer. J. Hum. Genet. 1993, 52, 827-834.
34. Lindsay, R. M. & J. D. Baty: Inter-individual variation of human blood N-acetyltransferase activity in vitro. Biochem. Pharmacol. 1988, 37, 3915-3921.
35. Matas, N., P. Thygesen, M. Stacey, A. Risch & E. Sim: Mapping AAC1, AAC2 and ACCP, the genes for the carcinogen metabolising enzymes, arylamine N-acetyltransferases, on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet. Cell Genet. 1997, 77, 290-295.
36. McQueen, C. A. & W. W. Weber: Characterization of human lymphocyte N-acetyltransferase and its relationship to isoniazid acetylator polymorphism. Biochem. Genet. 1980, 18, 889-903.
37. Minchin R. F.: Acetylation of p-aminobenzoylglutamate, a folic acid catabolite by recombinant arylamine N-acetyltransferase and U937 cells: Biochem. J. 1995, 307, 1-3.
38. Ohsako, S. & T. Deguchi: Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferase from human liver: J. Biol. Chem. 1990, 265, 4630-4634.
39. Okumura, K., T. Kita, S. Chikazawa, F. Komada, S. Iwakawa & Y. Tanigawara: Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin. Pharmacol. Therap. 1997, 61, 509-517.
40. Pacifici, G. M., C. Bencini & A. Rane: Acetyltransferases in humans: Development and tissue distribution. Pharmacology 1986, 32, 283-291.
41. Page, E. W.: Transfer of materials across the human placenta: Amer. J. Obstet. Gynaecol. 1957, 74, 705-718.
42. Payton, M. & E. Sim: Genotyping human arylamine N-acetyltransferase type-1 (NAT1): the identification of a novel mutation. Biochem. Pharmacol. 1998, 55, 361-366.
43. ProbstHensch, N. M., R. W. Haile, D. S. Li, G. T. Sakamoto, A. D. Louie, B. K. Lin, H. D. Prankl, E. R. Lee & H. J. Lin: Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 1996, 17, 2125-2129.
44. Risch, A., V. Smelt, D. Lane, L. Stanley, W. van der Slot, A. Ward & E. Sim: Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. Pharmacology & Toxicology 1996, 78, 235-240.
45. Simone, C., L. O. Derewlany & G. K. Koren: Drug transfer across the placenta. Fetal Drug Ther. 1994, 21, 463-481.
46. Simone, C. B. M. Byrne, L. O. Derewlany, M. Oskamp & G. Koren: The transfer of cocathylene across the human term placenta cotyledon perfused in vitro. Reprod. Toxicol. 1997, 11, 215-219.
47. Stanley, L. A., E. Coroneos, R. Cuff, D. Hickman, A. Ward & E. Sim: Immunochemical detection of arylamine N-acetyltransferases in normal and neoplastic bladder. J. Histochem. Cytochem. 1996, 44, 1059-1067.
48. Valdes, A. M., S. McWeeney & G. Thomson: HLA Class II DR-DQ amino acids and insulin-dependent diabetes mellitus: Application of the haplotype method. Amer. J. Hum. Genet. 1997, 60, 717-728.
49. Vatsis, K. P. & W. W. Weber: Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch. Biochem. Biophys. 1993, 301, 71-76.
50. Vatsis, K. P., W. W. Weber, D. A. Bell, J-M Dupret, D. A. Price Evans, D. M. Grant, D. W. Hein, H. J. Lin, U. A. Meyer, M. V. Relling, E. Sim, T. Suzuki & Y. Yamazoe: Nomenclature for N-acetyltransferases. Pharmacogenetics 1995, 5, 1-17.
51. Ward, A., D. Hickman, J. W. Gordon & E. Sim: Arylamine N-acetyltransferase in human red blood cells. Biochem. Pharmacol. 1992, 44, 1099-1104.
52. Ward A, M. Summers and E. Sim: Purification of recombinant human NAT1 expressed in E. coli and its potential role in folate metabolism. Biochem. Pharmacol. 1995, 49, 1759-1767.
53. Weber, W. W. & D. W. Hein: N-acetylation pharmacogenetics. Pharmacol. Rev. 1985, 37, 25-79.
54. Zhong, N., L. Ye, C. Dobkin, & W. T. Brown: Fragile X founder chromosome effects: Linkage disequilibrium or microsatellite heterogeneity? Am. J. Med. Genet. 1994, 51, 405-411.